The SNM's Clinical Trials Network, a project that addresses the need for streamlined drug discovery by using imaging biomarkers in multicenter clinical trials, has won another industry supporter, according to Reston, VA-based SNM.
Targeted therapeutic firm Genentech of South San Francisco, CA, has joined SNM's initiative, which brings together pharmaceutical developers, imaging vendors, biomarker manufacturers, and regulatory agencies. The use of imaging in clinical trials can help pharmaceutical developers determine earlier in the development process whether a new product is clinically promising by allowing physicians to assess whether it is working as intended for a patient.
The Clinical Trials Network was established late last year and launched in February 2009.
Related Reading
SNM hosts cardiovascular symposium, May 4, 2009
Prototype PET phantom successfully tested, April 15, 2009
SNM, CMOD plan May PET meeting, March 27, 2009
FDA clears SNM IND application, February 3, 2009
SNM criticizes NAS isotope report, January 16, 2009
Copyright © 2009 AuntMinnie.com
